Identity leadership (IL) describes that the effectiveness of a leader will depend upon his capacity to represent a given group, to make the group go forward, to create a group identity, and to make the group matter. An identity leader may increase commitment among his followers by increasing the perception of shared identity and giving more weight in the decision process to his followers. We aim to explore the mechanisms through which a leader who creates a shared group identity can increase organizational commitment. In the first study, we plan to conduct a cross-cultural correlational study where we aim to test if the relationship between IL and organizational commitment is mediated by team identification and mediated-moderated by participation in decision making (PDM) and collective efficacy. In the second study, we aim to explore the direction of the causality between IL and PDM. To test this hypothesis, we will conduct an experimental study in which (1) we will manipulate IL to test its influence on the perception of PDM and (2) we will manipulate PDM to test its influence on the perception of IL. Thus, we will be able to identify the role of IL and the perception of PDM on organizational commitment.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6144575 | PMC |
http://dx.doi.org/10.3389/fpsyg.2018.01677 | DOI Listing |
Appl Psychol Health Well Being
February 2025
College of Business, James Madison University, Harrisonburg, Virginia, USA.
As organizations are increasingly turning to voluntary wellness programs to improve employee well-being, the majority of studies in literature have focused on corporate-level benefits of wellness programs, such as productivity. However, there is a scarcity of studies that examine the intrinsic motivators that influence employee participation in such programs. In this study, we use a unique secondary dataset from a voluntary corporate wellness program and propose a novel theoretical framework based on motivational and behavioral theories to examine and understand the participants' behavior.
View Article and Find Full Text PDFAustralas Psychiatry
January 2025
University of the South Pacific, Suva, Fiji.
Creating Futures (CF) is an independent, collaborative taskforce supported by in-kind commitments from organisations and practitioners. This paper summarises CF 2023 themes and provides an overview of 20 years of CF activities. It highlights challenges and opportunities to integrate global mental health partnerships and regional mental health projects.
View Article and Find Full Text PDFBMC Psychol
January 2025
College of Special Education and College of Rehabilitation, Leshan Normal University, Leshan, Sichuan, 614004, China.
This study investigated the factors influencing teachers' organizational commitment in China. We employed a survey design with a sample of 506 full-time teachers from various public middle and high schools across mainland China. Social connectedness, job control, and work engagement were measured using self-reported scales.
View Article and Find Full Text PDFPLoS One
January 2025
Division of Emergency Medicine, University of Cape Town, Cape Town, South Africa.
To validate Palestine's previously derived emergency department quality standards (EDQS) using an e-Delphi survey. A two-round e-Delphi survey validated the EDQS, developed in an earlier study through a literature review and consensus-building among Palestinian emergency medicine and healthcare quality experts. The study purposively sampled 53 emergency department and healthcare quality experts with over 5 years of experience.
View Article and Find Full Text PDFCNS Drugs
January 2025
School of Medicine and Dentistry, Gold Coast Campus, Griffith University, Southport, QLD, 4222, Australia.
Background: Epstein-Barr virus (EBV) is implicated as a necessary factor in the development of multiple sclerosis (MS) and may also be a driver of disease activity. Although it is not clear whether ongoing viral replication is the driver for MS pathology, MS researchers have considered the prospect of using drugs with potential efficacy against EBV in the treatment of MS. We have undertaken scientific and lived experience expert panel reviews to shortlist existing licensed therapies that could be used in later-stage clinical trials in MS.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!